Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listipilimumab

ipilimumab

  • CAS NO.:477202-00-9
  • Molecular Weight: 0
  • MDL number: MFCD01864202
  • Update Date: 2024-10-28 16:48:35

What is ipilimumab?

Description

Ipilimumab is a CTLA-4 blocking antibody that was approved by the U.S. FDA in March 2011 for the treatment of unresectable or metastatic melanoma. Therefore, ipilimumab has an indirect effect on tumors that is mediated through blockade of CTLA-4 negative signaling and augmentation of T-cell activity. It is one of a handful of immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy.

Originator

Bristol-Myers Squibb (United States)

The Uses of ipilimumab

Treatment of oncology disease and HIV infection.

brand name

Yervoy

Mechanism of action

Anti-CTLA-4 monoclonal antibodies like ipilimumab inhibit CD80 and CD86 on APCs forms binding to CTLA-4 on T cells. The resulting blockade of CTLA-4 signaling prolongs T-cell activation, restores T-cell proliferation, and thus amplifies T-cell-mediated immunity, which theoretically enhances the patient's capacity to mount an antitumor immune response. Cancer patients with reduced CTLA-4 expression have shown a more pronounced response to blockade of the CTLA-4 pathway and less likelihood of subsequent relapse[1]. ipilimumab

Pharmacokinetics

Ipilimumab is a fully human monoclonal IgG1κ antibody. Limited pharmacokinetic data have been presented to date. However, a study of single-dose ipilimumab in patients with castrate-resistant prostate cancer showed that the pharmacokinetics of ipilimumab were consistent with other clinically used monoclonal antibodies tested in humans. The relatively long terminal half-life (12.5 days) means that a single dose of 3?mg/kg results in a serum concentration permitting dosing at 3–4 week intervals. Although the second-line, phase 3 trial used a dose of 3?mg/kg every 3 weeks for four doses without any maintenance, most trials initiated after 2006 use a dose of 10?mg/kg every 3 weeks for four doses and then one dose every 12 weeks for up to at least 3 years. The 10?mg/kg dose was selected based on superior clinical and pharmacokinetic data and a comparable safety profile[1].

Clinical Use

Antineoplastic agent:

Treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy

Side Effects

The more common side effects of ipilimumab include Bloody, black, or tarry stools; bone pain; chest pain or tightness; constipation; cough; depressed mood; diarrhea; dry skin and hair; feeling cold; fever; hair loss; heartburn; hoarseness or husky voice; indigestion; itching, skin rash; muscle cramps; nausea; pain in the arms or legs; severe stomach pain, cramping, or burning; slowed heartbeat; sneezing; sore throat; trouble breathing; unusual tiredness or weakness; vomiting; vomiting of material that looks like coffee grounds, severe and continuing; watery or bloody diarrhea.

Drug interactions

Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.

Metabolism

Most likely removed by opsonisation via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.

References

[1] Ahmad Tarhini, David R Minor, Ernest Lo. “Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.” Cancer Biotherapy and Radiopharmaceuticals 25 6 (2010): 601–13.

Properties of ipilimumab

form  Liquid
color  Colorless to light yellow

Safety information for ipilimumab

Computed Descriptors for ipilimumab

Related products of tetrahydrofuran

You may like

  • 7726-95-6 Bromine 99.5% AR (4 x 500ml) 99%
    7726-95-6 Bromine 99.5% AR (4 x 500ml) 99%
    7726-95-6
    View Details
  • Formamide 99%
    Formamide 99%
    75-12-7
    View Details
  • 376608-65-0 2-[[(3Ar,4S,6R,6As)-6-Aminotetrahydro-2,2-Dimethyl-4H-Cy 99%
    376608-65-0 2-[[(3Ar,4S,6R,6As)-6-Aminotetrahydro-2,2-Dimethyl-4H-Cy 99%
    376608-65-0
    View Details
  • 2, 4-Pyrimidinediamine 3-Oxide 99%
    2, 4-Pyrimidinediamine 3-Oxide 99%
    74638-76-9
    View Details
  • 111974-72-2 99%
    111974-72-2 99%
    111974-72-2
    View Details
  • 85-81-4 6-Methoxy-8-Nitroquinoline 99%
    85-81-4 6-Methoxy-8-Nitroquinoline 99%
    85-81-4
    View Details
  • 3-Bromo-4,5-Dihydro-1H-Benzo[B]Azepin-2(3H)-One 99%
    3-Bromo-4,5-Dihydro-1H-Benzo[B]Azepin-2(3H)-One 99%
    86499-96-9
    View Details
  • (−)-Dip-Chloride 85116-37-6 99%
    (−)-Dip-Chloride 85116-37-6 99%
    85116-37-6
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.